^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CC-1
i
Other names: CC-1, Bispecific PSMAxCD3 Antibody CC-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University Hospital Tuebingen
Drug class:
CD3 agonist, PSMA inhibitor
Related drugs:
10d
DKTK_PMO_1605: The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CC-1
7ms
ProSperACC-1: Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (clinicaltrials.gov)
P1, N=56, Recruiting, University Hospital Tuebingen | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CC-1
1year
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CC-1
over1year
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
P1/2, N=3, Terminated, German Cancer Research Center | N=86 --> 3 | Trial completion date: Sep 2025 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; premature termination of the trial due to bad recruitment
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Checkpoint inhibition • Checkpoint block
|
FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
|
FOLH1 expression
|
CC-1
2years
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Sep 2022 --> Aug 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
Trial completion date • Trial primary completion date
|
IL6 (Interleukin 6) • IL2 (Interleukin 2)
|
FOLH1 expression
|
CC-1
almost3years
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
P1/2, N=86, Recruiting, German Cancer Research Center | Not yet recruiting --> Recruiting
Enrollment open • Checkpoint inhibition
|
FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
|
FOLH1 expression
|
CC-1
3years
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
P1/2, N=86, Not yet recruiting, German Cancer Research Center | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: May 2023 --> Mar 2025
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
|
FOLH1 expression
|
CC-1
almost4years
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
P1/2, N=86, Not yet recruiting, German Cancer Research Center | Trial completion date: May 2024 --> Jan 2025 | Initiation date: Sep 2020 --> May 2021 | Trial primary completion date: Sep 2023 --> May 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
|
FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
|
FOLH1 expression
|
CC-1
Share via
